Skip to main content

Table 1 Patient and treatment characteristics

From: Pelvic Ewing sarcoma: a retrospective outcome analysis of 104 patients who underwent pelvic tumor resection at a single supra-regional center

 

All patients

Primary

Bone metastasis

Multifocal

Locally recurrent

Extraskeletal

LTFU

n

%

n

%

n

%

n

%

n

%

n

%

n

%

 

104

100

84

80.7

51

4.8

62

5.8

22

1.9

2

1.9

71

6.7

Sex

 Male

59

56.7

50

59.5

3

60

3

50

0

 

1

50

2

28.6

 Female

45

43.2

34

40.5

21

40

32

50

22

100

1

50

51

71.4

Age (years)

       

 Mean

18.1

17.5

17.8

29

19

18.5

15.7

 Range

2–53

2–53

12–26

12–45

12–24

15–22

9–26

Tumor size

 Mean (cm)

8.8

      

 < 9 cm

51

49

38

45.2

41

80

22

33.3

22

100

2

100

51

71.4

> 9 cm

43

41.3

38

45.2

1

20

3

50

0

 

0

 

1

14.3

 Unknown

10

9.6

8

9.5

0

 

1

16.6

0

 

0

 

1

14.3

Tumor volume

              

 < 200 ml

18

17.3

            

 > 200 ml

35

33.6

            

 Unknown

51

49

            

Tumor location

       

 Upper posterior

52

50

43

51.2

51

100

2

33.3

0

 

0

 

31

42.9

 Lower anterior

31

29.8

25

29.8

0

 

22

33.3

12

50

0

 

4

57.1

 Periacetabular

18

17.3

15

17.8

0

 

2

33.3

1

50

0

 

0

 

 Gluteal

2

1.9

0

 

0

 

0

 

0

 

2

100

0

 

 Unknown

1

0.9

1

1.2

0

 

0

 

0

 

0

 

0

 

Surgical procedure

 Internal intraarticular

51

49

43

51.2

0

 

22

33.3

12

50

1

50

5

71.4

 Internal extraarticular

13

12.5

9

10.7

0

 

2

33.3

1

50

1

50

0

 

 Internal (without joint involvement)

39

37.5

31

36.9

51

100

2

33.3

0

 

0

 

21

28.6

 Hindquarter amputation

1

0.9

1

1.2

0

 

0

 

0

 

0

 

0

 

Resection type (Enneking)

       

 P1a

3

2.9

0

 

31

60

0

 

0

 

0

 

11

14.3

 P1b

1

0.9

0

 

1

20

0

 

0

 

0

 

0

 

 P1-2

2

1.9

2

2.4

0

 

0

 

0

 

0

 

0

 

 P1c

31

29.8

27

32.1

1

20

2

33.3

0

 

0

 

1

14.3

 P1c + HS

2

1.9

2

2.4

0

 

0

 

0

 

0

 

0

 

 P1-2-3

2

1.9

2

2.4

0

 

0

 

0

 

0

 

0

 

 P1-2-4

14

13.5

11

13.1

0

 

0

 

0

 

2

100

1

14.3

 P1-2-4 + HS

2

1.9

2

2.4

0

 

0

 

0

 

0

 

0

 

 P1-2-3-4

15

14.4

12

14.3

0

 

2

33.3

1

50

0

 

0

 

 P1-2-3-4 + HS

1

0.9

1

1.2

0

 

0

 

0

 

0

 

0

 

 P2

1

0.9

0

 

0

 

0

 

0

 

0

 

1

14.3

 P2-3

14

13.5

12

14.3

0

 

12

16.6

12

50

0

 

1

14.3

 P3

15

14.4

12

14.3

0

 

1

16.6

0

 

0

 

2

28.6

 Unknown

1

0.9

1

1.2

0

 

0

 

0

 

0

 

0

 

Reconstruction types

       

 Hip transposition

33

31.7

            

 Hip transposition w/proximal femur replacement

9

8.7

            

 Hip transposition spacer

2

1.9

            

 Pelvic implant

1

0.9

Combined with hip transposition, n = 1

 Flail hip

1

0.9

Combined with hip transposition, n = 1

 Screw-rod reconstruction w/bone cement sheath

19

18.3

            

 Autologous iliac bone graft osteosynthesis

6

5.8

Combined with hip transposition, n = 1

 Autologous fibula bone graft osteosynthesis

5

4.8

Combined with hip transposition, n = 1

 Allograft osteosynthesis

7

6.7

            

 Soft tissue reconstruction only

21

20.2

            

EWSR 1 translocation status

 Present

62

59.6

      

 Absent

2

1.9

      

 Unknown

40

38.5

      

Histologic response to neoadjuvant chemotherapy (Salzer-Kuntschik)

       

 1 (no vital tumor)

54

51.9

46

54.8

51

100

1

16.6

0

 

0

 

31

42.9

 2 (isolated cells)

6

5.8

3

3.6

0

 

1

16.6

0

 

0

 

2

28.6

 3 (< 10% viable cells)

22

21.2

18

21.4

0

 

0

 

0

 

2

100

2

28.6

 4 (10–50% viable cells)

13

12.5

11

13.1

0

 

22

33.3

12

50

0

 

0

 

 5 (> 50% viable cells)

5

4.8

3

3.6

0

 

2

33.3

0

 

0

 

0

 

 6 (no response to chemo)

1

0.9

0

 

0

 

0

 

1

50

0

 

0

 

 Unknown

3

2.9

3

3.6

0

 

0

 

0

 

0

 

0

 

Surgical margins

              

 R0

98

94.2

78

92.8

51

100

62

100

22

100

2

100

71

100

 Planned R1

2

1.9

2

2.4

0

 

0

 

0

 

0

 

0

 

 Unplanned R1

2

1.9

2

2.4

0

 

0

 

0

 

0

 

0

 

 Unknown

2

1.9

2

2.4

0

 

0

 

0

 

0

 

0

 

Disease extent

 Localized

34

32.7

34

40.5

0

 

0

 

0

 

0

 

0

 

 Metastatic at diagnosis

45

43.3

30

35.7

51,3

100

62

100

22

100

2

100

21

28.6

 Metastatic after pelvic resection

17

16.3

17

20.2

0

 

0

 

0

 

0

 

0

 

 Unknown

8

7.7

3

3.6

0

 

0

 

0

 

0

 

5

71.4

Number of metastatic organ sites

       

 Single (one other organ system)

  

22

           

 Multiple (> 1 other organ systems)

  

7

           

Local recurrence

              
 

8

7.7

6

7.1

0

 

2

33.3

0

 

0

 

0

 

Radiation

 Yes

81

77.8

            

 Neoadjuvant

17

16.3

14

16.6

0

 

22,4

33.3

22

100

0

 

0

 

 Adjuvant

53

51

46

54.8

3

60

1

16.6

0

 

1

50

2

28.6

 Other

11

10.6

9

10.7

0

 

0

 

0

 

1

50

1

14.3

 No

17

16.3

12

14.3

21

40

3

50

0

 

0

 

11

14.3

 Unknown

6

5.8

3

3.6

0

 

0

 

0

 

0

 

3

42.9

  1. 1One patient with pelvic bone metastasis was also lost to follow-up
  2. 2One patient with locally recurrent ES after definite radiation and initially multifocal ES
  3. 3One patient presented with a metachronic solitary bone metastasis, received pelvic resection, and developed other distant metastases later on; four other patients presented with synchronous solitary pelvic bone metastasis
  4. 4Both locally recurrent patients received prior definite radiation